Official Title
Expanded Access Study of a Single Dose of Exebacase in Addition to Antistaphylococcal Antibiotics for the Treatment of Persistent Methicillin-Resistant Staphylococcus Aureus (MRSA) Bloodstream Infections (Including Right Sided Endocarditis) in Patients Who Are Hospitalized With Coronavirus Disease 2019 (COVID-19)
Brief Summary

This is an open-label, expanded access study of exebacase used in addition to antistaphylococcal antibiotics in adult patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI), including right-sided endocarditis (R-IE), who are hospitalized with coronavirus disease 2019 (COVID-19). Patients with left-sided endocarditis (L-IE) are excluded. Patients will receive a single dose of exebacase. Patients will continue to receive antistaphylococcal antibiotics as prescribed by the treating physician. Exebacase Phase 3 study sites (Study CF-301-105) may participate in this Expanded Access study (Study CF-301-107). Exebacase, a direct lytic agent, is an entirely new treatment modality against S. aureus. Exebacase is a recombinantly-produced, purified cell wall hydrolase enzyme that results in rapid bacteriolysis, potent biofilm eradication, synergy with antibiotics, low propensity for resistance, and the potential to suppress antibiotic resistance when used together with antibiotics. Exebacase represents a first-in-field, first-in-class treatment with the potential to improve clinical outcome when used in addition to standard-of-care antibiotics to treat S. aureus BSI including IE.

No longer available
Intermediate-size Population
MRSA Bloodstream Infection
MRSA Bacteremia
MRSA Right-sided Endocarditis

Drug: Exebacase

Patients will receive a single IV infusion of exebacase in addition to antistaphylococcal antibiotics prescribed by the treating physician. Patients with normal renal function or mild renal impairment will be administered a dose of 18 mg of exebacase; patients with moderate or severe renal impairment will be administered a dose of 12 mg; patients with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg.

Eligibility Criteria

Inclusion Criteria:

- Male or female, 18 years of age or older.

- Hospitalized with known COVID-19 infection confirmed by positive diagnostic test.

- Not eligible for the exebacase Phase 3 study (CF-301-105).

- Blood cultures positive for MRSA for ≥3 days.

- Patient is not pregnant or breastfeeding and is not of reproductive potential or
agrees to remain abstinent or use contraception if of reproductive potential.

Exclusion Criteria:

- Known or suspected left-sided IE.

- Intubated for COVID-19.

- Presence of prosthetic valve or cardiac valve support ring, or presence of known
infected orthopedic hardware, prosthetic joint, or cardiac device.

- Known or suspected brain abscess or meningitis.

- Participation in an investigational study or expanded access protocol for another
antistaphylococcal antibacterial agent.

Eligibility Gender
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
United States

CF-301-107 Study Site
Butte, Montana, United States

Cf 301-107
Toledo, Ohio, United States

NCT Number
MeSH Terms